RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients.
Dablu Lal GuptaJhasketan MeherAnjan Kumar GiriArvind K ShuklaEli MohapatraManisha M RuikarD N RaoPublished in: Drug target insights (2024)
The amino acid substitutions at the RBD of SARS-CoV-2 have been associated with a higher potential to escape the humoral immune response.